Diabetes is an established risk factor for pancreatic cancer (PaC), together with obesity, a Western diet, and tobacco smoking. The common mechanistic link might be the accumulation of advanced glycation end-products (AGEs), which characterizes all of the above disease conditions and unhealthy habits. Surprisingly, however, the role of AGEs in PaC has not been examined yet, despite the evidence of a tumour-promoting role of receptor for advanced glycation end-products (RAGE), the receptor for AGEs. Here, we tested the hypothesis that AGEs promote PaC through RAGE activation. To this end, we investigated the effects of the AGE N  -carboxymethyllysine ( 
Introduction
Diabetes mellitus (DM), the prevalence of which is expected to increase dramatically [1] , has been identified as a risk factor for a variety of malignancies, including pancreatic cancer (PaC) [2] . The incidence of PaC continues to increase, and it is predicted to become the second cause of cancer-related deaths in the USA by 2030 [3] . As no effective therapy is available for the majority of patients, and the 5-year survival is <7% [3] , it is important to focus on prevention by eliminating risk factors.
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found to regulate the crosstalk between prosurvival pathways in pancreatic ductal adenocarcinoma (PDA) cells [11] . RAGE interacts with multiple exogenous and endogenous ligands to induce inflammation [12] , and is expressed in cell types implicated in tumour formation [13] . As such, RAGE has been linked to cancer development/progression by facilitating the maintenance of a chronic inflammatory state [14] and/or by promoting tumour growth [15] . More specifically, RAGE ligation activates nuclear factor-κB (NF-κB), a critical transcription factor transducing a variety of inflammatory signals [16] and upregulating RAGE itself, as the gene encoding RAGE (termed AGER in human) contains functional binding elements for NF-κB [17] .
The name RAGE derives from its ability to bind advanced glycation end-products (AGEs). Although a role for these major RAGE ligands has been tentatively proposed to explain the increased risk of various cancers (including PaC) in diabetic and obese individuals [18] , surprisingly, their role in pancreatic carcinogenesis has never been investigated [19] . AGEs comprise a heterogeneous group of compounds [20] that accumulate in tissues of ageing individuals and, at an accelerated rate, in diabetic and obese subjects, owing to mechanisms including increased carbohydrate and lipid substrate availability, oxidative and non-oxidative conditions favouring the glycation process, and impaired detoxification [21] . In addition to endogenous production, high-temperature-processed foods and cigarette smoking are major environmental sources of AGEs [22, 23] , which might therefore be involved in the increased PaC risk associated with dietary and smoking habits [24] . Consistent with the involvement of the AGE-RAGE axis in human PaC, a large prospective study reported that plasma levels of soluble RAGE (sRAGE), a truncated circulating form acting as a decoy receptor in preventing RAGE activation [25] , were inversely associated with the risk of PaC among Finnish male smokers [26] .
This study investigated the tumour-promoting role of N ε -carboxymethyllysine (CML), a major AGE found in vivo [27] and a known RAGE ligand [28] , in a well-characterized genetically engineered mouse model of human PaC and in PDA cell lines.
Materials and methods

Study design
The in vitro study was designed to investigate the tumour-promoting effects of CML on PDA cell lines by evaluating cell growth and the main tumourigenic pathways involved in PaC promotion. A secondary objective was to assess whether these effects were RAGE-mediated. The in vivo study was designed to evaluate the effect of CML on the progression of early murine pancreatic neoplasia. The primary and secondary endpoints were the development of invasive PaC and the development/progression of PanINs, respectively. The number of mice was not prespecified. According to the Ethics Committee recommendation, to limit the number of animals, the experiments were stopped when the data were sufficient to confirm or reject the working hypothesis in a statistically and clinically meaningful manner. Biological samples were recoded by a technician (C.C., see Acknowledgements) at the time of collection, and analysed by investigators blinded to group assignment. The research protocol was approved by the National Ethics Committee for Animal Experimentation of the Italian Ministry of Health (Authorization no. 1470/2015-PR). The mice were housed in single cages and cared for according to standards articulated in the Animal Research: Reporting of In Vivo Experiments (ARRIVE) (https://www.nc3rs .org.uk/arrive-guidelines) guidelines.
Cell lines
Human MIA PaCa-2 and PANC-1 (PDA) cells (Sigma-Aldrich, St Louis, MO, USA) and the normal human pancreatic duct epithelial (HPDE) cell line HPDE-E6E76c7 (H6C7) (kindly provided by M. Fanciulli, Regina Elena National Cancer Institute, Rome, Italy) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, and incubated with native human serum albumin (HSA) [Sigma-Aldrich; vehicle, control (Ctr)] or CML-modified HSA (1-100 μg/ml CML) with or without the S100P-derived RAGE antagonist peptide (RAP) (Calbiochem, Merck, Darmstadt, Germany; 10 μmol/l, added daily). CML was prepared as previously reported [21, 29] . Characterization of CML preparations by the use of 2,4,6-trinitrobenzene sulphonic acid revealed that 13.2 ± 2.1% and 14.7 ± 2.4% of total free amino groups (lysine and arginine) in CML-modified HSA and CML-modified mouse serum albumin (MSA), respectively, were modified. This rate of modification was previously found to enable the binding of RAGE [28] , but not of scavenger receptors [30] , and is comparable with that detected in serum proteins of diabetic patients [31] . RAGE binding to the CML-modified MSA preparation used in the in vivo studies was confirmed in a functional enzyme-linked immunosorbent assay (ELISA) (supplementary material, Figure S1 ). The RAP concentration was chosen on the basis of the available literature data [9] . Detailed information on CML preparation, characterization and RAGE-binding activity is provided in supplementary material, Supplementary materials and methods.
AGEs as a diabetes-related risk factor for pancreatic cancer 199 RAGE and molecular targets of tumourigenic signalling pathways in PDA cells
The mRNA levels of the genes coding for (1) RAGE, (2) CD166/activated leukocyte cell adhesion molecule (ALCAM), a close structural and functional homologue of RAGE [32] , (3) nuclear factor of activated T-cells cytoplasmic 1 (NFATC1) and serine/threonine protein kinase Pim-1 (PIM1), two signal transducer and activator of transcription 3 (STAT3) downstream targets that have been implicated in inflammation-driven PaC [33] and (4) interleukin (IL)-6, the production of which has been shown to be RAGE-dependent in Pdx1-Cre;LSL-Kras G12D/+ (KC) mice [10] (AGER, ALCAM, NFATC1, PIM1, and IL6, respectively) were assessed by real-time polymerase chain reaction (RT-PCR) with a StepOne Real-Time PCR System and TaqMan Gene Expression assays (Applied Biosystems, Monza, Italy), and are listed in supplementary material, Table S1 [34, 35] .
Nuclear protein extracts were obtained from cell monolayers with the Nuclear Extract Kit (Active Motif Corp., Carlsbad, CA, USA). Nuclear protein levels of NF-κB/p65, phosphorylated STAT3 (p-STAT3), NFATC1 and hypoxia-inducible factor (HIF)-1α, which is involved in RAGE-Kras promotion of PaC [10] , were assessed by western blotting (see supplementary material, Table S2 for antibodies). The DNA-binding activities of NF-κB/p65 and HIF-1α were assessed with the TransAM NFkB p65 and HIF-1 kits, respectively (Active Motif Corp.). Details of RAGE neutralization experiments with anti-RAGE antibody are provided in supplementary material, Supplementary materials and methods.
Transgenic mouse model
The effect of CML administration on PaC development through RAGE activation was investigated in genetically engineered mice, i.e. KC mice, on a C57BL/6 background, which develop autochthonous lethal PaC in a pattern recapitulating human PDA with high fidelity [36] . KC mice were interbred with mitosis luciferase (MITO-Luc) reporter mice on an FVB background [37, 38] to obtain KC-Mito (KCM) mice (supplementary material, Supplementary materials and methods). Five-week old KCM mice were randomly assigned to treatment with daily intraperitoneal injections of 30 μg of native MSA (Ctr mice) or CML-modified MSA [21] . At this age, the pancreatic parenchyma is histologically normal, and early-stage PanINs are rarely observed [36, 38] . The treatment dose was chosen on the basis of our previous data showing that this injection protocol results in a two-fold to three fold increase in circulating and tissue AGE levels [21, 39] , similar to what is observed in experimentally diabetic mice [29, 34, 40, 41] . We subjected Ctr and CML-treated mice to longitudinal in vivo bioluminescence imaging (BLI) imaging and manual palpation of the abdomen to monitor tumour development. Additional groups of KCM mice were treated with 100 μg/day RAP [9] in addition to native MSA (Ctr + RAP) or CML-modified MSA (CML + RAP).
In vivo imaging of cell proliferation in PaC
Starting from the fifth week of age, in vivo imaging [37, 38] was carried out every other week as previously reported [38] . Briefly, 10 min after administration of D-luciferin (75 mg/kg body weight, intraperitoneal; Perkin Elmer, Hopkinton, MA, USA), photon emission from the different body areas was acquired for 5 min and analysed with a CCD camera (Xenogen IVIS Lumina System; Perkin Elmer). A specific region of interest (ROI) corresponding to the abdominal area occupied by the pancreas was manually selected, and light emission from this ROI was evaluated with Living Image software (Caliper Life Sciences; Perkin Elmer). Data were expressed as photons/second/cm 2 /steradiant (p/s/cm 2 /sr).
Ex vivo imaging
At the end of treatment, mice were anaesthetized for in vivo imaging, and then killed by cervical dislocation. The pancreas was dissected and exposed to the CCD camera for 5 min for photon emission assessment. Samples were divided; one part was frozen and kept at -80 ∘ C for molecular analysis, and the other part was embedded in paraffin for histological analysis and immunohistochemistry (IHC).
Pancreas histology
At least six 4-μm-thick non-serial pancreatic sections were stained with haematoxylin and eosin (H&E) and examined to confirm the presence of cancer or dysplastic ducts, graded according to previously established criteria [36] . KCM and KC mice develop, with complete penetrance, ductal lesions identical to all three stages of human PanINs [36, 42] . The numbers of low-grade (PanIN-1A/B) and high-grade (PanIN-2/3) dysplastic ducts were counted, and expressed as a percentage of total ducts in the specimen [10] .
Pancreatic protein levels of RAGE and CD166/ALCAM, co-localization of RAGE with CML, and phosphorylation status of STAT3
The pancreatic tissue distribution of RAGE and CD166/ALCAM was analysed by IHC. Co-localization of RAGE and CML was analysed by dual-label immunofluorescence, as described in supplementary material, Supplementary materials and methods. Pancreatic protein levels of p-STAT3, RAGE and CD166/ALCAM were assessed by western blotting (see supplementary material, Table S2 , for antibodies). For western blot analysis, proteins were separated on a TGX Stain-Free Gel (Bio-Rad Laboratories, Hercules, CA, USA), as detailed in supplementary material, Supplementary materials and methods.
S Menini et al
Serum levels of AGE CML, soluble RAGE (sRAGE), and IL-6
Serum levels of CML, sRAGE and IL-6 were assessed with ELISA (Cell Biolabs, San Diego, CA, USA, for CML; R&D Systems, Minneapolis, MN, USA, for sRAGE and IL-6) [34, 35] . Lack of interference of circulating sRAGE and RAP with CML assays and of CML and RAP with sRAGE assays were verified by adding increasing concentrations of each of these ligands to serum prior to performing the ELISAs (supplementary material, Figure S2 ). Details are provided in supplementary material, Supplementary materials and methods.
Statistical analysis
Results are expressed as mean ± standard deviation and/or percentage. Differences between cell types/treatments or animal groups were assessed with Student's t-test or one-way ANOVA followed by the Student-Newman-Keuls test for multiple comparisons, as appropriate. Differences among animal groups in PaC prevalence at 11 weeks of age were assessed with Fisher's exact test to compute a P value from a contingency table. A P value of <0.05 was considered to be significant. All statistical tests were performed on raw data with SPSS 13.0.
Results
CML promotes PDA cell proliferation and induces RAGE upregulation
CML promoted proliferation of MIA PaCa-2 cells in a time-dependent and concentration-dependent manner ( Figure 1A ,B). Dose-dependent induction of proliferation was also observed in PANC-1 cells, peaking at 10 μg/ml ( Figure 1C ), whereas HPDE cells responded only at the lowest concentration tested ( Figure 1D ). Induction of proliferation was accompanied by increased RAGE expression in all three cell lines ( Figure 1A-D) . Interestingly, the CML concentration range with a positive dose-response relationship for proliferation at 24 h correlated with baseline RAGE expression ( Figure 1E ).
The AGE-RAGE axis modulates tumourigenic pathways involved in PaC CML treatment increased NK-κB/p65 protein levels and activation (Figure 2A ,B) and p-STAT3 nuclear content (Figure 2A) , and induced the transcriptional activity of the STAT3 target genes NFATC1 and PIM1 ( Figure 2C ). RAP treatment counteracted all of the molecular events elicited by CML, and completely prevented CML-induced proliferation of PDA cells ( Figure 2D ). In addition, RAP inhibited CML-induced nuclear translocation of HIF-1α and its DNA-binding activity, nuclear translocation of NFATC1, activation of HIF-1α, and upregulation of IL-6 (supplementary material, Figure S3 ). Proliferation and NF-κB nuclear translocation induced by CML were also inhibited by an anti-RAGE antibody in MIA PaCa-2 culture (supplementary material, Figure S4 ). Expression of the RAGE homologue ALCAM [32] was not detectable (MIA PaCa-2) or was at the limit of detectability (PANC-1) in PDA cells untreated or treated with CML or CML + RAP for 24 h.
CML favours the development and progression of early murine PaC
After 6 weeks of treatment with CML (i.e. at 11 weeks of age), more than half of the KCM mice (6/11) showed positive abdominal imaging, and approximately one in four (3/11) had a palpable abdominal mass (supplementary material, Figure 3A) . At this age, only one Ctr-KCM mouse showed significant abdominal photon emission (supplementary material, Figure S5 ). Therefore, to avoid loss of CML-treated KCM mice and limit the number of animals, the study was stopped at this time. However, as in vivo imaging does not allow clear identification of the organ/tissue contributing to the BLI signal, we performed ex vivo imaging of the gastrointestinal organs at the time of killing, which confirmed that specific spots of BLI signals were mainly emitted by the pancreatic mass ( Figure 3B ). On histological analysis, invasive PDA was confirmed in eight of 11 (72.7%) CML-treated mice, as compared with one of 11 (9.1%) Ctr mice (Table 1) . Therefore, the majority of Ctr mice showed normal pancreatic architecture, although preinvasive PanINs of various degrees were observed in all specimens analysed ( Figure 3C ). Conversely, the majority of CML-treated KCM mice showed a diffusely infiltrative PDA with well-differentiated and poorly differentiated areas within the same tumour ( Figure 3C,D) ; scattered low-grade and high-grade PanINs were also seen, especially at the tumour border ( Figure 3E ). These histological features were also observed in the pancreas from the one Ctr-KCM mice with invasive PaC, consistent with previous reports [33, 34] . No liver or lung metastases were observed grossly or in serial sections in both groups at this age (Table 1) .
CML increases RAGE protein levels in PanINs and well-differentiated regions of invasive PaC of KCM mice IHC for RAGE in pancreatic sections of CML-treated KCM mice showed intense staining of PanINs, but not of the surrounding acinar tissue ( Figure 4A,B) . Cytoplasmic granular RAGE positivity was also observed in cells of duct-like structures in well-differentiated regions of the tumour, but not in surrounding undifferentiated areas ( Figure 4C ). PanINs of Ctr-KCM mice were also positive for RAGE, although the staining with CML in PanINs of CML-treated KCM mice, but not of Ctr-KCM mice ( Figure 4E ). Western blotting demonstrated higher RAGE levels in pancreatic specimens of CML-treated mice with well-differentiated PaC ( Figure 4F ), and significantly increased p-STAT3 levels in CML-treated KCM mice versus Ctr-KCM mice (supplementary material, Figure S6 ).
RAP delays PanIN lesion development in Ctr-KCM mice but fails to prevent CML-induced PaC promotion and progression
As assessed by histology, none of the 10 KCM mice treated with RAP (Ctr + RAP) showed invasive PaC at 11 weeks of age (Table 1) . However, quantitative analysis of neoplastic ducts showed that the numbers of low-grade and, particularly, high-grade PanIN lesions were significantly reduced in Ctr + RAP-treated KCM mice as compared with Ctr-KCM mice ( Figure 5 ). Conversely, RAP administration did not counteract the promoting effect of CML on pancreatic tumourigenesis, as demonstrated by the high rate (six of seven mice, 87.5%) of invasive PaC observed in CML + RAP-treated KCM mice (Table 1) . What is more, liver and/or lung metastases were observed grossly and confirmed by histological examination in three of seven mice (42.5%) ( Table 1 ; supplementary material, Figure S7 ). Finally, western blotting and IHC revealed a sharp increase in the level of the RAGE homologue CD166/ALCAM in mice treated with CML + RAP versus those receiving CML alone, but not in mice given RAP only (Figure 5D ,E; supplementary material, Figure S8 ).
RAP + CML treatment reduces serum levels of sRAGE and increases the CML/sRAGE ratio
As expected, serum levels of CML were increased in KCM mice treated with CML and CML + RAP ( Figure 6A ). Conversely, serum sRAGE levels were reduced by CML treatment, and further reduced by combined CML + RAP treatment ( Figure 6B) . As a result, the serum CML/sRAGE ratio (i.e. free or not sRAGE-associated CML) was higher in CML + RAP-treated KCM mice than in CML-treated KCM mice ( Figure 6C ). Consistent with a role of RAGE in IL-6 production, levels of this cytokine were increased in KCM mice treated with CML, and were partly reduced by RAP treatment ( Figure 6D ).
Discussion
This study provides the first experimental evidence that the AGE CML (1) modulates the activity of signalling pathways involved in PaC development and stimulates cell proliferation in PDA cell lines in a RAGE-dependent manner, and (2) accelerates progression from PanINs to invasive PaC in a mouse model of Kras-driven PaC. Our results also support previous data demonstrating a permissive role for RAGE in early pancreatic neoplasia [10] and the efficacy of RAGE ablation/blockade in delaying PaC development in the presence of physiological levels of AGEs [9, 10] . However, our data argue against the utility of RAGE blockade/inhibition as a therapeutic option in conditions characterized by increased circulating in DM and other conditions characterized by increased AGE accumulation. The in vitro experiments demonstrated that CML stimulates proliferation of human PDA cell lines through RAGE activation, thus suggesting a role for the AGE-RAGE axis in PaC promotion. Several lines of evidence support this interpretation. First, the time-dependent and concentration-dependent stimulation of cell proliferation by CML was accompanied by parallel upregulation of RAGE expression and downstream tumourigenic pathways. Second, RAGE blockade with RAP counteracted the effects of CML on cell proliferation, NF-κB activation, and STAT3 phosphorylation and upregulation of its target genes. Third, the higher the basal expression of RAGE (i.e. MIA PaCa-2 > PANC-1 > HPDE), the larger was the range of CML levels with a positive dose-response relationship for cell growth. This RAGE-dependent heterogeneity in the cell proliferative response to different AGE levels might represent one of the mechanisms through which DM promotes PaC. In fact, the high levels of AGEs characterizing DM may favour the proliferation of initially transformed cells, which show a high level of RAGE as compared with non-transformed cells.
The in vivo studies assessing the effect of CML on early pancreatic carcinogenesis showed that this AGE accelerates the development of PaC in KCM mice. Although a considerable degree of variability exists in the total PaC burden among coeval mice, at 11 weeks of age both KC [36, 42] and KCM [38] mice showed a substantial number of PanIN lesions (∼30% of pancreatic ducts), most of which of were low grade, and usually no invasive lesions. Therefore, the finding of one of 11 Ctr-KCM mice with PaC should be considered as an occasional observation. Conversely, the finding that eight of 11 CML-treated KCM mice presented with invasive PaC indicates that AGEs markedly accelerate PaC development. In addition, the content and distribution of RAGE and CML in pancreatic lesions strongly support the hypothesis that CML-enhanced tumourigenesis is mediated through RAGE expression and activation, in keeping with previous data showing that RAGE expression increases in parallel with the progression of PanIN lesions in KC mice and is upregulated in human PaC specimens [10] . Moreover, the pronounced RAGE staining detected in cells of duct-like structures in well-differentiated regions of PaC, but not in the surrounding undifferentiated areas, suggests that RAGE is dispensable for subsequent steps of tumour progression. Taken together, these data support the hypothesis of a permissive role of RAGE for the progression of PanIN lesions to invasive PaC, as previously demonstrated in KC-RAGE knockout mice [10] .
In accord with this assumption, we were able to demonstrate that RAGE blockade with RAP reduced the formation and progression of PanINs in KCM mice, consistent with a previous report in a pancreatic orthotopic model [9] . However, one of the main aims of our study was to verify the hypothesis that blockade of the AGE-RAGE axis might represent a targeted risk reduction therapy for PaC in high-risk individuals such as those with metabolic disorders and unhealthy lifestyle habits [2, 26, 43, 44] , who show elevated circulating levels of AGEs [22, 23] . In contrast to our expectations, and at variance with data from cell culture studies and Ctr-KCM mice, RAGE blockade with RAP did not prevent the promoting effect of CML on pancreatic carcinogenesis, and even favoured tumour spreading and metastasis. These findings seem to argue against a role of the AGE-RAGE axis in the tumour-promoting effect of CML. However, two lines of evidence indicate they may have been related to two effects of RAP that were observed only when it was administered to mice with pathological levels of CML (CML + RAP treatment). First, the CML/sRAGE ratio (i.e. free CML) was higher in KCM mice treated with CML + RAP than in those treated with CML alone, suggesting that, in the presence of high circulating CML levels, RAP competes with CML for binding to sRAGE, thus reducing the decoy receptor activity of this circulating form of RAGE generated by both alternative splicing and ectodomain shedding of full-length RAGE. The resulting higher levels of free CML may have favoured CML-induced tumour promotion. This interpretation is consistent with the concept that serum sRAGE levels represent a promising biomarker and therapeutic target in metabolic and neoplastic disorders [45, 46] . Second, the protein levels of the RAGE homologue CD166/ALCAM [32] were higher in PaC specimens from KCM mice treated with CML + RAP than in those treated only with CML (and also those treated with RAP only). This finding suggests that, again only in the presence of high circulating levels of CML, RAGE blockade results in AGE-induced upregulation of CD166/ALCAM and/or favours the clonal expansion of PaC cells expressing this RAGE homologue [32] . The finding that neither CML nor CML + RAP treatment of PDA cells for 24 h was able to modify basal ALCAM mRNA expression indicates that this is a gradual process involving in vivo tumour heterogeneity and clone selection. This interpretation is consistent with the observation that CD166/ALCAM shares with RAGE some endogenous ligands, and is compensatorily upregulated after genetic deletion of its counterpart [32] . In addition, it is supported by the finding that increased tumour levels of CD166/ALCAM in KCM mice treated with CML + RAP were associated with tumour spread, in keeping with the notions that this RAGE homologue is typically restricted to subsets of cells involved in dynamic growth and migration [47] and is an independent prognostic marker for poor survival and early tumour relapse in PaC [48] . However, the findings in mice treated with CML + RAP should be confirmed in RAGE knockout mice treated with CML, although, in our hands, RAP treatment provided similar protective effects to those induced by RAGE ablation in mice not treated with CML [10] . Another limitation of our study is the lack of analytical techniques to confirm data on CML serum levels obtained by ELISA, although immunological and analytical methods were shown to produce comparable results in similar conditions [49] .
In summary, our data demonstrate that the AGE-RAGE axis modulates PaC development in a genetically engineered mouse model of the disease, as shown by the acceleration of PanIN progression to PaC and the concurrent upregulation of RAGE induced by the AGE CML. This finding provides a conceivable molecular mechanism to explain the increased risk of PaC conferred by DM and other conditions with increased AGE accumulation. However, RAGE blockade with RAP was ineffective in protecting against CML-induced promotion of tumourigenesis, probably because of competition with sRAGE for binding to AGEs and compensatory upregulation of CD166/ALCAM and/or clonal expansion of tumour cells expressing this RAGE homologue. Taken together, these results suggest that an AGE reduction strategy might be more suitable than RAGE blockade for reducing the PaC risk associated with DM, obesity, a Western diet, and tobacco smoking. Figure S1 . Analysis of the binding of RAGE to immobilized CML-MSA in a functional ELISA Figure S2 . Validation of the ELISA kits for the determination of sRAGE and CML serum levels 
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